Precigen Management

Management criteria checks 2/4

Precigen's CEO is Helen Sabzevari, appointed in Jan 2020, has a tenure of 4.75 years. total yearly compensation is $3.72M, comprised of 26.9% salary and 73.1% bonuses, including company stock and options. directly owns 0.77% of the company’s shares, worth $1.87M. The average tenure of the management team and the board of directors is 4.8 years and 10.5 years respectively.

Key information

Helen Sabzevari

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage26.9%
CEO tenure4.8yrs
CEO ownership0.8%
Management average tenure4.8yrs
Board average tenure10.5yrs

Recent management updates

Recent updates

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Feb 28
We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Jan 20

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Nov 04
Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Jul 18
Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

May 15
Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18
Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10
Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10
Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12
Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

May 10
Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

The Prognosis On Precigen

Jan 05

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Dec 31
Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

CEO Compensation Analysis

How has Helen Sabzevari's remuneration changed compared to Precigen's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$135m

Mar 31 2024n/an/a

-US$97m

Dec 31 2023US$4mUS$1m

-US$96m

Sep 30 2023n/an/a

-US$85m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$79m

Dec 31 2022US$3mUS$1m

-US$80m

Sep 30 2022n/an/a

-US$84m

Jun 30 2022n/an/a

-US$103m

Mar 31 2022n/an/a

-US$108m

Dec 31 2021US$3mUS$1m

-US$111m

Sep 30 2021n/an/a

-US$124m

Jun 30 2021n/an/a

-US$125m

Mar 31 2021n/an/a

-US$110m

Dec 31 2020US$20mUS$1m

-US$104m

Sep 30 2020n/an/a

-US$100m

Jun 30 2020n/an/a

-US$122m

Mar 31 2020n/an/a

-US$138m

Dec 31 2019US$1mUS$500k

-US$169m

Sep 30 2019n/an/a

-US$373m

Jun 30 2019n/an/a

-US$381m

Mar 31 2019n/an/a

-US$414m

Dec 31 2018US$3mUS$500k

-US$375m

Compensation vs Market: Helen's total compensation ($USD3.72M) is above average for companies of similar size in the US market ($USD1.45M).

Compensation vs Earnings: Helen's compensation has increased whilst the company is unprofitable.


CEO

Helen Sabzevari (62 yo)

4.8yrs

Tenure

US$3,719,061

Compensation

Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intre...


Leadership Team

NamePositionTenureCompensationOwnership
Randal Kirk
Executive Chairman16.7yrsUS$600.00k0.40%
$ 964.3k
Helen Sabzevari
President4.8yrsUS$3.72m0.77%
$ 1.9m
Harry Thomasian
Chief Financial Officer3yrsUS$1.13m0.080%
$ 193.3k
Rutul Shah
Chief Operating Officerno dataUS$1.04m0.073%
$ 176.7k
Donald Lehr
Chief Legal Officer & Corporate Secretary13.8yrsUS$1.06m0.19%
$ 453.4k
Jeffrey Perez
Senior Vice President of Intellectual Property Affairs10.2yrsUS$872.09k0.26%
$ 626.1k
Steven Harasym
VP & Head of Investor Relations6.8yrsno datano data
Rob Russell
VP & Head of Human Resourcesno datano datano data
Douglas Brough
Senior VP & Head of Researchno datano datano data
Bryan Butman
Senior VP & Head of CMCno datano datano data
Amy Lankford
Senior VP & Head of Clinical Operations and Regulatory Affairs1.3yrsno datano data
Phil Tennant
Chief Commercial Officerless than a yearno datano data

4.8yrs

Average Tenure

62yo

Average Age

Experienced Management: PGEN's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Randal Kirk
Executive Chairman16.7yrsUS$600.00k0.40%
$ 964.3k
Helen Sabzevari
President4.3yrsUS$3.72m0.77%
$ 1.9m
Jeffrey Kindler
Independent Director12.9yrsUS$319.00k0.14%
$ 331.5k
Fred Hassan
Independent Director8.3yrsUS$306.50k0.36%
$ 867.7k
Cesar Alvarez
Independent Director16.7yrsUS$312.50k0.20%
$ 480.2k
James Turley
Lead Independent Director10.5yrsUS$312.50k0.16%
$ 398.1k
Steven Frank
Independent Director16.7yrsUS$300.00k0.36%
$ 863.0k
Nancy Agee
Independent Directorless than a yearno data0.0061%
$ 14.8k
Vinita Gupta
Independent Director7.5yrsUS$306.50k0.16%
$ 383.9k

10.5yrs

Average Tenure

69yo

Average Age

Experienced Board: PGEN's board of directors are seasoned and experienced ( 10.5 years average tenure).